Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Interim data reported from ongoing phase Ib study of EDP-1815 in psoriasis

Aug. 7, 2019

Complete wound healing reported in first patient treated in phase II study of RGN-137

Aug. 6, 2019

Sanofi reports updates for Dupixent as treatment in adolescents and children with atopic dermatitis

Aug. 6, 2019

Lifesci Pharmaceuticals divulges KLKB1 inhibitors

Aug. 2, 2019

Phase II study of ATI-501 in alopecia areata meets primary endpoint

July 31, 2019

Activation of neuronal TRPV1 is sufficient to cause the equivalent of psoriasis

July 26, 2019

Arcutis reports promising topline phase IIb data on ARQ-151 for plaque psoriasis

July 23, 2019

Swedish MPA approves first-in-human trial of ILP-100

July 22, 2019

Affibody completes 12-week interim analysis of phase II psoriasis study of ABY-035

July 17, 2019

Galderma describes new mTOR inhibitors

July 15, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...